Actieve functies van Pablo Umaña
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Hoofd Techniek/Wetenschap/O&O | 01-09-2000 | - |
| Oprichter | 01-09-2000 | - |
Loopbaan van Pablo Umaña
Eerdere bekende functies van Pablo Umaña
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ROCHE HOLDING AG | Corporate Officer/Principal | - | - |
Statistieken
Internationaal
| Zwitserland | 2 |
| Verenigde Staten | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
- Beurs
- Insiders
- Pablo Umaña
- Ervaring
